AI assistant
Sending…
Eton Pharmaceuticals, Inc. — Director's Dealing 2025
Jan 6, 2025
32663_dirs_2025-01-06_36d78c26-3806-4626-a0da-8b8b5e2811d3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2025-01-03
Reporting Person: RIEDEL NORBERT G (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-03 | Employee Stock Option (Right to Buy) | $13 | A | 25000 | Acquired | 2035-01-02 | Common Stock (25000) | Direct |
Footnotes
F1: The shares subject to the option shall vest equally on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 3, 2026.
More from Eton Pharmaceuticals, Inc.
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Regulatory Filings
2026
Apr 27
Board/Management Information
2026
Apr 16
Annual Report
2026
Mar 19
Earnings Release
2026
Mar 19
Capital/Financing Update
2026
Mar 2
Regulatory Filings
2026
Feb 25
Director's Dealing
2026
Feb 5